Latest Health News

Pacific Edge announces a two-month delay in the Medicare Local Coverage Determination for its genetic oncology tests, extending the effective date to April 24, 2025. This extension follows the company’s active engagement with US regulatory bodies.

Oneview Healthcare reported a robust Q4 2024 cash flow update, bolstered by a significant equity raise and expanding partnerships, positioning the company for accelerated growth in 2025.

InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.

8VI Holdings Limited has confirmed its voluntary delisting from the ASX, reporting a challenging quarter marked by declining cash reserves and a strategic pivot towards preventive care that is yet to yield significant revenue.

Metrics Real Estate Multi-Strategy Fund has announced an estimated ordinary dividend of AUD 0.0096 per security, with key dates set for late January and early February 2025. The dividend is unfranked and relates to the financial period ending January 31, 2025.

Supply Network Limited projects a solid half-year profit of $19.8 million and announces a fully franked interim dividend of 32.0 cents per share, signaling steady financial health ahead of its full results.

Global Masters Fund Limited's latest quarterly report confirms compliance with all financial obligations and highlights a recent interest rate increase on its convertible notes, supported by a robust loan-to-value ratio.

ECP Emerging Growth Limited has reported steady financial health and full compliance with its convertible notes obligations for the quarter ended December 2024, maintaining a conservative loan-to-value ratio and an unchanged conversion price.

Volt Resources Limited has successfully repaid a AU$500,000 loan to RiverFort Global Opportunities, underscoring its financial discipline amid ongoing graphite project developments.

Respiri Limited reports a standout December quarter marked by a 67% surge in patient program enrolments and robust revenue growth, bolstered by strategic acquisition synergies from Orb Health. The company is poised for further expansion in 2025 amid promising contract negotiations and evolving US healthcare reimbursement policies.

4DMedical has signed a landmark commercial agreement with Qscan Radiology Clinics, marking its first Australian contract to integrate both Pulmonary Function and Pulmonary Structure imaging products.

Biotron Limited has engaged US-based C14 Consulting Group to drive strategic partnerships for its antiviral drug portfolio, including lead candidate BIT225, while advancing its Hepatitis B research.